Your session is about to expire
← Back to Search
Enhanced Hearing Screening + Telemedicine Referral for Childhood Hearing Loss
N/A
Recruiting
Led By Matt Bush, MD, PhD, MBA
Research Sponsored by University of Arkansas
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up school screening occurs once per school year, with timing and practices varying by school.
Awards & highlights
No Placebo-Only Group
Summary
This trial will evaluate a new way of screening for and referring children with hearing problems in rural schools, using mobile health tools and telemedicine.
Who is the study for?
This trial is for children entering elementary school in one of the 14 participating counties in rural Kentucky. It's open to all kids, no matter their age, gender, race, or ethnicity. There are no specific exclusion criteria mentioned.
What is being tested?
The study tests a new approach (STAR model) that uses mobile health tools and telemedicine to improve hearing loss screening and follow-up care in rural schools. It includes an enhanced mHealth screening with tympanometry and a specialty telemedicine referral process.
What are the potential side effects?
Since this trial involves non-invasive screening methods and referrals rather than direct medical treatments or drugs, there are likely minimal to no side effects associated with participation.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ school screening occurs once per school year, with timing and practices varying by school.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~school screening occurs once per school year, with timing and practices varying by school.
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Proportion of children screened
Proportion of children who receive follow-up
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Sequence 2Experimental Treatment3 Interventions
Standard Hearing Screening: All counties in Sequence 2 will receive standard hearing screening in the control period, Years 1 and 2
Standard Referral: All counties in Sequence 2 will receive standard referral in control period, Years 1, 2 and 3.
Enhanced mHealth screening component: Counties randomized to Sequence 2 will receive the enhanced mHealth screening in Years 3 and 4.
Specialty telemedicine referral component: Counties randomized to Sequence 2 will receive the specialty telemedicine referral component in addition to the enhanced mHealth screening in Year 4.
Group II: Sequence 1Experimental Treatment3 Interventions
Standard School Screening: All counties in Sequence 1 will receive standard hearing screening in the control period, Year 1
Standard Referral: All counties in Sequence 1 will receive standard referral in control period, Years 1 and 2.
Enhanced mHealth screening component: Counties randomized to Sequence 1 will receive the enhanced mHealth screening in Years 2, 3, and 4.
Specialty telemedicine referral component: Counties randomized to Sequence 1 will receive the specialty telemedicine referral component in addition to the enhanced mHealth screening in Years 3 and 4.
Find a Location
Who is running the clinical trial?
Duke UniversityOTHER
2,452 Previous Clinical Trials
2,957,391 Total Patients Enrolled
8 Trials studying Hearing Loss
39,184 Patients Enrolled for Hearing Loss
National Institutes of Health (NIH)NIH
2,811 Previous Clinical Trials
8,146,858 Total Patients Enrolled
8 Trials studying Hearing Loss
1,640 Patients Enrolled for Hearing Loss
University of KentuckyOTHER
191 Previous Clinical Trials
209,122 Total Patients Enrolled
3 Trials studying Hearing Loss
65 Patients Enrolled for Hearing Loss
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- N/AMy eligibility is not limited by my age, gender, race, or ethnicity.
Research Study Groups:
This trial has the following groups:- Group 1: Sequence 1
- Group 2: Sequence 2
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger